Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...

In July last year, after the Lok Sabha elections, the Health Ministry was allocated Rs 90958.63 crore in the Union Budget 2024-25.

The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap biotech stocks are worth a closer look.

Additionally, newer therapies like pertuzumab (Perjeta) and trastuzumab deruxtecan (Enhertu) have improved outcomes, providing more options for patients. “The key part of developing a molecular ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...